Biohaven Accepts Presentation on FGFR3 ADC at EORTC Symposium
What happened
Biohaven Ltd. announced that data regarding BHV-1530 has been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). The presentation details the findings of the Phase 1 study of BHV-1530, a first-in-class FGFR3-directed antibody-drug conjugate. This study incorporates Biohaven's proprietary TopoIx payload and has shown early clinical activity with a tolerable safety profile.
From prnewswire.com
Why it matters
The symposium serves as a leading international forum for early-phase oncology drug development. Biohaven has also begun enrolling patients for the study in combination with cemiplimab (Libtayo) under a clinical supply agreement with Regeneron Pharmaceuticals, Inc.
From prnewswire.com
Who's involved
- BarcelonaLocation of the symposium in Barcelona, Spain
Keep exploring
The entities involved
-
Barcelona
city in Catalonia, Spain
-
African Democratic Congress
Nigerian Polictical Party
Related events
- Elections are set to move closer to polling stage for the African Democratic Congress in Agartala.
- The All Progressives Congress and African Democratic Congress are contesting senatorial seats in the 2027 elections.
- All Progressives Congress views the African Democratic Congress's ticket as a political experiment.
- Opposition parties struggle to form a united front.
- A dispute regarding political priorities has emerged involving the African Democratic Congress and APA in Zamfara State.